Nuvectis Pharma, Inc. Stock Price, News & Analysis

Nuvectis Pharma (NASDAQ: NVCT) will host a virtual Key Opinion Leader meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b program in advanced solid tumors, including the combination with osimertinib in non-small cell lung cancer (NSCLC).

Speakers include Alexander Spira, MD, PhD, FACP, FASCO and Asier Uncita-Broceta, MPharm, MSc, PhD, who will join company management to review preclinical and clinical data to date, strategy for monotherapy and combination arms, and a live Q&A. A replay will be posted on the company's Investors page.

Nuvectis Pharma (NASDAQ: NVCT) reported Q3 2025 results and clinical updates on Nov 4, 2025. Key clinical milestones include initiation of the NXP900 Phase 1b single-agent study with combination dosing expected by year-end, completion of the Phase 1a dose-escalation showing robust pharmacodynamic responses, and a completed drug-drug interaction study supporting combination strategies. Poster presentations at the 2025 AACR-NCI-EORTC conference highlighted the emerging clinical profile and biomarker-based patient selection approach. Financially, cash and cash equivalents were $35.4M as of Sept 30, 2025, with a cash runway expected into 3Q-2027. Net loss was $7.5M in Q3 2025, up from $4.2M a year earlier.

Nuvectis Pharma (NASDAQ: NVCT) reported third-quarter 2025 results and operational updates on Nov. 4, 2025. Key clinical progress: NXP900 Phase 1b monotherapy component has commenced, the Phase 1a dose-escalation study completed with robust pharmacodynamic responses at clinically relevant once-daily doses, and a clinical drug-drug interaction study in healthy volunteers was completed supporting planned combination therapy. Poster presentations at the 2025 AACR-NCI-EORTC conference highlighted NXP900's emerging clinical profile and biomarker-based patient selection strategy. Financials: cash and cash equivalents $35.4M as of Sept 30, 2025 (vs $18.5M Dec 31, 2024), with cash runway expected into 3Q-2027. Q3 net loss was $7.5M, up from $4.2M year-ago, reflecting a $2.0M milestone and higher clinical costs.

Nuvectis Pharma (NASDAQ: NVCT) reported poster highlights for NXP900 presented at the 2025 AACR-NCI-EORTC conference. In a Phase 1a dose-escalation program (33 patients), NXP900 given once daily at 20–300 mg showed an acceptable safety profile with mostly Grade 1–2 diarrhea, fatigue and nausea, and elicited a robust pharmacodynamic response at doses ≥150 mg/day. A clinical drug-drug interaction study in healthy volunteers found no induction of key CYP450 enzymes. Preclinical FAT1‑mutant xenograft data showed tumor growth inhibition and YAP1 pathway suppression. The Phase 1b single‑agent study in tumors with YES1, FAT1, NF2 alterations is ongoing (NCT05873686); combination dosing is planned to start in the near term.

Nuvectis Pharma (NASDAQ: NVCT) announced poster presentations for its investigational candidate NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, taking place October 22–26, 2025.

Two posters will appear in Poster Session A on October 23, 2025, 12:30–4:00 PM ET: LB-A019 covering clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions (presenter Gerald Falchook, MD), and A099 reporting that NXP900 potently inhibits tumor growth in FAT1‑mutated xenograft models (presenter Asier Unciti‑Broceta).

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company, has appointed Dr. Juan Sanchez to its Board of Directors. Dr. Sanchez most recently served as VP of Corporate Communications and Investor Relations at Intra-Cellular Therapies, which was acquired by Johnson & Johnson for $14.6 billion in April 2025.

Dr. Sanchez brings over 30 years of experience spanning patient care, Wall Street research analysis, and biopharmaceutical executive leadership. His appointment comes as Nuvectis prepares to initiate its Phase 1b program for NXP900, targeting advanced and treatment-resistant cancers.

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision oncology medicines, has announced its participation in the H.C. Wainwright Global Investment Conference.

Chairman and CEO Ron Bentsur will deliver a corporate presentation that will be available for on-demand viewing by conference attendees starting September 5, 2025, at 7:00 a.m. ET. The company will also participate in virtual one-on-one meetings during the conference, which runs from September 8-10, 2025.

Nuvectis Pharma (NASDAQ: NVCT) has announced the initiation of its Phase 1b program for NXP900, following successful completion of dose escalation and drug-drug interaction studies. The program consists of two components: a single-agent study evaluating NXP900 in patients with specific genetic alterations, and a combination study with EGFR and ALK inhibitors in NSCLC patients who developed treatment resistance.

The single-agent component targets patients with YES1 amplification, FAT1 mutations in NSCLC, NF2 mutations in mesothelioma and renal cancer, and other solid tumors with relevant Hippo Pathway alterations. The combination study, expected to start later in 2025, will focus on NSCLC patients who developed resistance to existing treatments.

Nuvectis Pharma (NASDAQ: NVCT) reported significant progress in Q2 2025, highlighted by the successful completion of NXP900's Phase 1a dose escalation study in advanced solid tumors and a drug-drug interaction study in healthy volunteers. The company strengthened its financial position with a proforma cash balance of $39 million as of June 30, 2025, following an ATM share acquisition by a healthcare-focused institutional investor in July.

The company reported a net loss of $6.3 million for Q2 2025, compared to $4.4 million in Q2 2024. R&D expenses increased to $3.6 million, while G&A expenses rose to $3.0 million. The current cash position is expected to fund operations into second half of 2027, with plans to initiate the NXP900 Phase 1b program imminently and explore NXP800's potential in endometrial and prostate cancers.